Sector News

Evotec says Sanofi deal makes it anti-infectives powerhouse

June 18, 2018
Life sciences

It’s taken more than three months to work through the detail, but Sanofi has now signed a deal to transfer its anti-infectives unit to Evotec.

The main elements of the agreement remain unchanged form when it was announced in March. Around 100 Sanofi employees will go onto Evotec’s payroll but will stay at the its site in Lyons, and more than 10 infectious disease R&D programmes will be transferred to the German biotech. Sanofi is also stumping up €60m in initial funding and says it will provide “significant” ongoing support without specifying numbers.

The deal comes after extensive negotiations with France’s powerful unions and government officials over the job security of the French employees under their new management, and the deal includes “specific long-term commitments of employment,” according to Evotec. It’s been reported that that includes five-year employment contracts.

The aim is to inject some biotech-style nimbleness and flexibility into Sanofi’s anti-infectives portfolio, and also for the unit to become an open science focal point – bringing together other “companies, foundations, academia, and government agencies,” says Evotec. That essentially means getting other research groups to put drug candidates through Evotec’s R&D platform, and tapping into public funding sources.

For its part, Sanofi is hanging onto options to develop and commercialise any potential product candidates from its contributed projects.

Evotec’s CEO Dr Werner Lanthaler (pictured) said that the biotech will have around 180 scientists working in this area when the transaction completes in the next few weeks – subject to regulatory approvals of course – and that will give it “the highest qualified translational footprint in infectious disease research globally.” It will focus initially on antimicrobial resistant (AMR) infections, tuberculosis, and malaria, as well as new-mechanism antiviral drugs.

Last month, Evotec’s chief scientific officer Cord Dohrmann said that the new R&D unit will have “one of the largest infectious disease drug discovery platforms and pipelines [with] over 20 projects” mainly in antimicrobial and antiviral therapy. Sanofi’s vaccines unit wasn’t included in the deal, and most of the projects being transferred are in the discovery or preclinical stages.

For Sanofi, the spin-out reflects not only the challenging nature of anti-infectives research, but also changing priorities at the French drugmaker, which is in the midst of a major revamp of its pipeline following the acquisitions of Ablynx and Bioverativ.

By Phil Taylor

Source: PMLive

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).